Search

Corvus Pharmaceuticals Inc

Geschlossen

9.64 1.69

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

9.48

Max

9.61

Schlüsselkennzahlen

By Trading Economics

Einkommen

-4.3M

-18M

EPS

-0.19

Angestellte

37

EBITDA

-5.3M

-17M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+209.87% upside

Dividenden

By Acuity

Nächstes Ergebnis

3. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-286M

839M

Vorheriger Eröffnungskurs

7.95

Vorheriger Schlusskurs

9.64

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Okt. 2026, 23:51 UTC

RBA's Assistant Governor Kent addresses interest rates amid rising inflation and global market pressures, signaling cautious investor sentiment.

18. Okt. 2026, 23:51 UTC

China's Q3 GDP Growth Forecast at +1.1% Amid Mixed Economic Sentiment and Global Challenges

18. Okt. 2026, 23:51 UTC

Bank of Korea Expected to Maintain 3% Interest Rate Amid Inflation and Economic Growth Concerns

18. Okt. 2026, 23:51 UTC

NAHB Housing Market Index Expected to Drop to 31.0 Amid Declining Builder Sentiment and Economic Pressures Ahead of October Release.

18. Okt. 2026, 23:41 UTC

China's Q3 2026 GDP Growth Rate Expected to Rise Slightly to 4.4% Amidst Cautious Optimism and Economic Challenges

18. Okt. 2026, 23:41 UTC

Canada's Retail Sales Ex Autos Expected to Rise 1.2% MoM for August Amid Mixed Economic Sentiment

18. Okt. 2026, 23:41 UTC

China's Retail Sales Expected to Rise 0.5% YoY in September Amidst Cautious Economic Sentiment, Release Scheduled for October 19, 2026

18. Okt. 2026, 23:41 UTC

China's Industrial Production YoY data for September 2026 is set to release on October 19, with a forecast growth of 5.4%, reflecting cautious optimism in the market amid potential impacts on PBOC monetary policy.

18. Okt. 2026, 23:41 UTC

China's Fixed Asset Investment Expected to Decline by -7.3% YoY, Raising Market Concerns Ahead of Key Economic Data Release on October 19, 2026

18. Okt. 2026, 23:32 UTC

News

Arthur Hayes stated on social media that quantum computing should not deter Bitcoin investment and cautioned against the security risks of reusing wallet addresses.

18. Okt. 2026, 23:32 UTC

Macro News
News

Bitcoin is trading modestly higher, with Arthur Hayes noting that quantum computing concerns shouldn't deter investors from holding the asset.

18. Okt. 2026, 23:31 UTC

Correlated Moves
Macro News

Prices rise amid higher crude oil and geopolitical tensions.

18. Okt. 2026, 23:31 UTC

Correlated Moves

XRP is advancing, reflecting a broader upward movement in the cryptocurrency space, as Bitcoin has also gained slightly since the previous close.

18. Okt. 2026, 23:21 UTC

China's Loan Prime Rate Expected to Hold Steady at 3.0% Amid Economic Uncertainties Ahead of October 20 Announcement

18. Okt. 2026, 23:21 UTC

China's Loan Prime Rate Expected to Hold at 3.5% Amid Mixed Economic Signals and Geopolitical Tensions

18. Okt. 2026, 23:11 UTC

China's House Price Index YoY release on October 19, 2026, shows ongoing housing market challenges with a previous decline of -3.0%, as analysts watch for potential stabilization from recent government interventions amid cautious investor sentiment.

18. Okt. 2026, 23:01 UTC

The EUR/CZK is trading roughly flat as macroeconomic challenges and inflation data raise concerns about potential interest rate hikes by the Federal Reserve.

18. Okt. 2026, 23:01 UTC

Macro News
Correlated Moves

The Nasdaq 100 Index is modestly higher, supported by a $5 billion U.S. initiative to enhance power line capacity amid rising electricity demand.

18. Okt. 2026, 23:01 UTC

Macro News
Correlated Moves

Silver is modestly higher as tensions between Ukraine and Russia escalate, impacting global energy markets, while Gold remains little changed amid ongoing gains.

18. Okt. 2026, 23:01 UTC

Macro News

Platinum prices are lower amid geopolitical tensions from Ukrainian drone strikes and the U.S. Energy Department's $5 billion initiative affecting energy supply dynamics.

18. Okt. 2026, 23:01 UTC

Correlated Moves
Macro News

The U.S. Energy Department announced a $5 billion initiative to enhance power line capacity across 26 states, boosting grid efficiency amid rising electricity demand.

18. Okt. 2026, 23:01 UTC

Macro News

Natural gas prices are declining, continuing a downward trend amid geopolitical tensions and rising U.S. fuel costs, with prices below the 20-day moving average.

18. Okt. 2026, 23:01 UTC

Macro News

Oil prices are declining as the U.S.-Iran conflict impacts global markets, contributing to rising fuel costs, with gasoline averaging $4.33 per gallon.

18. Okt. 2026, 23:01 UTC

Correlated Moves
Macro News

The Russell 2000 Index is higher amid concerns over inflation and potential Fed interest rate hikes, alongside a $5 billion U.S. energy initiative.

18. Okt. 2026, 23:01 UTC

The EUR/CHF currency pair is trading lower as the new week begins, influenced by concerns over potential Federal Reserve interest rate hikes amid rising inflation.

18. Okt. 2026, 23:01 UTC

The GBP/AUD is trading modestly lower as the new trading week begins, following a retracement from an early peak amid broader market concerns.

18. Okt. 2026, 23:01 UTC

The EUR/NZD is declining in early trading, influenced by higher-than-expected inflation data and concerns over potential Federal Reserve interest rate hikes.

18. Okt. 2026, 23:01 UTC

The EUR/JPY is trading modestly lower as the new trading week begins, following a notable decline and concerns over potential Fed interest rate hikes.

18. Okt. 2026, 23:01 UTC

The EUR/AUD is trading lower at the start of the new week, continuing Friday's decline amid concerns over inflation and potential interest rate hikes.

18. Okt. 2026, 23:01 UTC

GBP/CAD is lower as trading resumes for the week, influenced by recent inflation data raising concerns over potential Federal Reserve interest rate hikes.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

209.87% Vorteil

12-Monats-Prognose

Durchschnitt 29.5 USD  209.87%

Hoch 33 USD

Tief 27 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat